# A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07365319/  
OnCo record `nct07365319` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing EIK1001 in non-small-cell lung cancer, now recruiting.

## Summary

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT07365319, led by Eikon Therapeutics with Merck Sharp & Dohme, and recruiting on the registry. Official title: A Global, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008). Planned enrolment is 750 participants (estimated). The study started in 2026-06-15 and primary completion is expected in 2035-12-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: TeLuRide-008
- Tags: ctgov-ingest
- Registry id: NCT07365319
- Phase: 2/3
- Setting: A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008)
- Sponsor: Eikon Therapeutics
- Enrolled: 750

## Sources

- ClinicalTrials.gov NCT07365319: https://clinicaltrials.gov/study/NCT07365319

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [EIK1001](https://onco.cc/drugs/eik1001/)
- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07365319.json